Company news
Aprea Therapeutics, Inc. (NASDAQ:APRE) news
Aprea Therapeutics, Inc. news releases on 6ix. Latest, Oct 5, 2026: Aprea Therapeutics to Present at October Conferences
Press releases & updates
Aprea Therapeutics to Present at October Conferences
October 5, 2026
Aprea Therapeutics to Present at October Conferences
October 4, 2026
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
September 22, 2026
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
August 28, 2026
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
August 12, 2026
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
July 30, 2026
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
June 1, 2026
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 13, 2026
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
March 31, 2026
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
March 29, 2026
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 15, 2026
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
February 17, 2026
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
February 12, 2026
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
February 4, 2026
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
January 29, 2026
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 29, 2026
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
December 18, 2025
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 9, 2025
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
November 12, 2025
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
October 24, 2025
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
October 15, 2025
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2025
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
August 28, 2025
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
August 12, 2025
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
June 25, 2025
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
May 14, 2025
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
March 31, 2025
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
March 25, 2025
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
March 11, 2025
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
February 4, 2025
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
December 10, 2024
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
October 9, 2024
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
October 8, 2024
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 11, 2024
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
June 16, 2024
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
May 27, 2024
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
May 13, 2024
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 1, 2024
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
April 9, 2024
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
March 25, 2024
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
March 10, 2024
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
March 4, 2024
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
February 5, 2024
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
January 3, 2024
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 8, 2023
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 18, 2023
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors
September 10, 2023
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
August 23, 2023